MYOV - Karuna Program Progress And Other News: The Good Bad And Ugly Of Biopharma
Karuna Therapeutics Reports Positive News for Acute Psychosis Treatment
Karuna Therapeutics, Inc. (KRTX) reported that it plans to proceed with its clinical program assessing KarXT for the treatment of acute psychosis in patients with schizophrenia. The company stated that it has completed a successful End-of-Phase 2 meeting with the FDA and the outcome supports the advancement of the drug candidate into Phase 3 development.
The End-of-Phase 2 discussion was supported by pre-clinical and clinical efficacy data and included results from its Phase 2 trial assessing KarXT in patients with schizophrenia. Andrew Miller, Ph.D.,